Table 3 Post procedure outcomes

Technical Success

100% (95% CI 90.5–100%)

Clinical Success

29/37(78%) (95% CI 62–90%)

 Venous segment

P = 0.22

  • IVC

4/5 (80%)

  • Iliac/Iliocaval

18/21 (86%)

  • Iliofemoral

7/11 (64%)

 Laterality

P = 0.06

  • Unilateral

13/20 (65%)

  • Bilateral

12/12 (100%)

 Stent type

P = 0.4

  • Nitinol stent

9/13 (69%)

  • Wall Stent

13/16 (81%)

  • Combination

6/7 (86%)

  • Covered stent

1/1 (100%)

 Dedicated venous stent^a

P = 0.7

  • Yes

7/9

  • No

15/20

  • Combination

7/8

 DVT

P = 0.6

  • Tumor thrombus

1/2(50%)

  • Bland thrombus

16/20(80%)

  • No thrombus

12/15(80%)

 RTH

P = 0.4

  • Yes

10/14(71%)

  • No

19/23(82.6%)

 Survival

  • Median Survival

4.7 months (95% CI 3.58–5.99)

  • 30-day mortality

5.4%

  • 1 year mortality

77.4%

Proportion of patent stents

26 (79%, 95% CI 61%-91%)

 Venous segment

P = 0.28

  • IVC

2/4

  • Iliac/Iliocaval

16/20

  • Iliofemoral

8/9

 Stent type

P = 0.88

  • Nitinol stent

9/11

  • Wall Stent

11/15

  • Combination

5/6

  • Covered stent

1/1

 DVT

P = 0.57

  • Tumor thrombus

1/2(50%)

  • Bland thrombus

14/17(82%)

  • No thrombus

11/14(79%)

 RTH

P = 1.0

  • Yes

11/14(79%)

  • No

15/19(79%)

 Type of last follow up imaging

  • US

7

  • CT with contrast

22

  • CTV

10

  • MRI with contrast

1